Unknown

Dataset Information

0

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.


ABSTRACT: INTRODUCTION:The double-blind, phase 3 PREEMPT trials demonstrated the efficacy and tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. This post hoc analysis evaluated the effect of onabotulinumtoxinA on clinically meaningful changes in headache severity, headache-related impact, and quality of life. METHODS:Pooled, 24-week data were used to determine percentages of patients meeting responder criteria for the change in headache days (??50% reduction in headache-day frequency), Headache Impact Test (HIT-6;???5-point improvement), MSQ Role Function-Restrictive (MSQ-RFR;???10.9-point improvement), and Average Daily Headache Severity (ADHS;???1-point improvement on a 4-point ordinal scale [0?=?no pain, 3?=?severe pain]). RESULTS:In the pooled analysis population (N?=?1384; onabotulinumtoxinA, n?=?688; placebo, n?=?696), significantly more patients treated with onabotulinumtoxinA compared with placebo were responders on HIT-6 (40.8 vs. 25.3%), MSQ-RFR (59.0 vs. 40.2%), and ADHS (35.5 vs. 22.4%) measures, and achieved traditional???50% reduction in headache days (44.8 vs. 34.2%; all P?

SUBMITTER: Diener HC 

PROVIDER: S-EPMC7648806 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7648816 | BioStudies
2016-01-01 | S-EPMC4959035 | BioStudies
2015-01-01 | S-EPMC4552933 | BioStudies
2017-01-01 | S-EPMC5539058 | BioStudies
2014-01-01 | S-EPMC4033567 | BioStudies
2019-01-01 | S-EPMC6734221 | BioStudies
2019-01-01 | S-EPMC6734222 | BioStudies
2019-01-01 | S-EPMC6734507 | BioStudies
2019-01-01 | S-EPMC6537129 | BioStudies
2017-01-01 | S-EPMC5734384 | BioStudies